About us
Your risks have changed.
When you are a biopharma company, a PE firm or an investor with a vested interest in bringing a new medicine to market, you need to understand how.
The critical path has shifted
Where clinical trials and their scientific outcomes were on the critical path for many decades, it has now shifted to getting the product manufactured and to patients safely and on time. Every day of delay is $500k of missed sales.
Forty years of outsourcing
For forty years, manufacturing and supply chains have been outsourced. Siloed organisations cause quality issues, handover problems and missing capabilities and skills. Spotting and addressing these risks early is critical for success, and for getting the planned revenue in the books. More importantly, addressing them lowers the chance that the patient is impacted.
Let us help you
Our very experienced, senior team has seen and lived through these challenges. We assess clinical, regulatory, manufacturing and supply risk as one, for FDA and EMA markets, so you see what could stall the asset before you sign. One joint Delay Risk Review of a pharma or biotech deal, before the investment committee, with fixed timelines, scope and fee.
Call us for an introduction call on your asset and let's talk.
"Every day of delay is $500k of missed sales."
Book an introduction call with us